Amended and Restated Employment Agreement between Precision BioSciences, Inc. and Dario Scimeca, dated November 7, 2022
Exhibit 10.4
EXECUTIVE EMPLOYMENT AGREEMENT AMENDMENT
This Executive Employment Agreement Amendment (the “Amendment”) is made as of November 7, 2022, by and among Precision BioSciences, Inc. (the “Company”) and the individual whose name appears on the signature page hereto (the “Executive”). Except as set forth in this Amendment, capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below).
WITNESSETH
WHEREAS, the Executive previously entered into an executive employment agreement with the Company (the “Employment Agreement”); and
WHEREAS, the Executive and the Company each desire to amend the terms of the Employment Agreement as set forth in this Amendment.
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Executive and the Company hereby agree to the following:
“a material, adverse change in Executive’s title, authority, duties, or responsibilities (other than temporarily while the Executive is physically or mentally incapacitated or as required by applicable law), provided that this shall not apply following an acquisition of or merger by the Company if Executive is provided with similar title, responsibilities, duties and authority in a larger organization, but only with respect to the business of the Company and its subsidiaries;”
[signature page follows]
|
IN WITNESS WHEREOF, the Company and the Employee have executed this Amendment as of the date first written above.
PRECISION BIOSCIENCES, INC.
By: /s/ Michael Amoroso
Name: Michael Amoroso
Title: Chief Executive Officer
EXECUTIVE
/s/ Dario Scimeca
Dario Scimeca
|